CymaBay Therapeutics (CBAY) Tops Q2 EPS by 33c

CymaBay Therapeutics (NASDAQ: CBAY) reported Q2 EPS of ($0.09), $0.33 better than the analyst estimate of ($0.42).

For earnings history and earnings-related data on CymaBay Therapeutics (CBAY) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance